Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the presentation of new preclinical data for its lead drug ...

Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 ...

Alkanediols such as 1,6-hexanediol disrupt many phase-separated condensates in cellula and in vitro, but how molecular interactions are perturbed by these compounds remains unclear. This study uses ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

said that the EchoBack CAR T-cells function by being activated by ultrasound in the tumour location. From there, the CAR T-cells continue to seek and destroy cancer cells for at least five days ...

Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology drugs.

Gain expert insights in this interview on achieving transfection success. Explore proven strategies to optimize your approach and enhance results.

Primary Immunodeficiency (PID) in India poses a significant health concern, with under-recognition hindering diagnosis and treatment accessibility.

A common malaria drug could be repurposed to treat a variety of hematologic cancers and solid tumors, according to early ...

Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association for Cancer Research (AACR) 2025 Annual ...

Findings could open up new avenue for precision therapy for the most commonly diagnosed cancer among women that killed 670,000 in 2022 alone A team of Chinese scientists has uncovered a key mechanism ...